|Bid||0.00 x 3200|
|Ask||0.00 x 3100|
|Day's Range||5.49 - 5.67|
|52 Week Range||1.82 - 7.80|
|Beta (5Y Monthly)||0.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 29, 2023 - Apr 03, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.41|
Subscribe to Yahoo Finance Plus to view Fair Value for CTIC
CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee's acceptance of employment with the company. The equity award was approved on January 23, 2023, in accordance
CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco.
Here is how CTI BioPharma (CTIC) and Esperion Therapeutics (ESPR) have performed compared to their sector so far this year.